Literature DB >> 17417085

Magnetic resonance imaging of uterine malignancies.

Camilla R Whitten1, Nandita M DeSouza.   

Abstract

Magnetic Resonance Imaging (MRI) is the criterion standard in the assessment and staging of uterine cancer because of the high tissue contrast between glandular lining and inner and outer muscle layers of the uterine corpus and cervix on T2-weighted scans. It is also an essential tool in monitoring treatment response and in assessing disease recurrence in these patients. The key to a successful examination lies in good patient preparation, use of antiperistaltic agents, and a meticulous scanning technique. Endometrial carcinomas are the most common uterine malignancy, occurring in a primarily postmenopausal population. Dynamic contrast-enhanced scans may be required in addition to T2-weighted images to assess the presence of myometrial invasion in this age group. Cervical cancers occur in a younger population and are readily assessed with T2-weighted imaging. Use of an endovaginal receiver coil allows high spatial resolution imaging of the cervix, which is particularly useful when assessing patients for fertility-sparing procedures such as trachelectomy. Uterine sarcomas are 1% to 3% of all uterine malignancies and usually arise from a mixture of homologous and heterologous elements. Rarely, lymphoma, small cell carcinoma and metastatic deposits involve the uterus. This review summarizes the optimal scanning techniques for demonstrating uterine malignancy and discusses the role of imaging and the MRI appearances of uterine tumors.

Entities:  

Mesh:

Year:  2006        PMID: 17417085     DOI: 10.1097/RMR.0b013e3180417d47

Source DB:  PubMed          Journal:  Top Magn Reson Imaging        ISSN: 0899-3459


  1 in total

1.  Evaluating Myometrial Invasion in Endometrial Cancer: Comparison of Reduced Field-of-view Diffusion-weighted Imaging and Dynamic Contrast-enhanced MR Imaging.

Authors:  Mayumi Takeuchi; Kenji Matsuzaki; Masafumi Harada
Journal:  Magn Reson Med Sci       Date:  2017-05-18       Impact factor: 2.471

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.